Lactobacillus rhamnosus and Lactobacillus delbrueckii Ameliorate the Expression of miR-125a and miR-146a in Systemic Lupus Erythematosus Patients.
Autoimmune disease
Lactobacillus
Lupus
MicroRNA
Probiotic
Journal
Applied biochemistry and biotechnology
ISSN: 1559-0291
Titre abrégé: Appl Biochem Biotechnol
Pays: United States
ID NLM: 8208561
Informations de publication
Date de publication:
14 Feb 2024
14 Feb 2024
Historique:
accepted:
19
12
2023
medline:
14
2
2024
pubmed:
14
2
2024
entrez:
14
2
2024
Statut:
aheadofprint
Résumé
The microRNAs are non-coding RNA molecules involved in physiological and pathological processes, causing autoimmune diseases such as systemic lupus erythematosus (SLE). Probiotics are living microorganisms that possess beneficial effects on the host immune system and modulate it. The effect of Lactobacillus rhamnosus and Lactobacillus delbrueckii on the expression of miR-125a and miR-146a was studied in peripheral blood mononuclear cells (PBMCs) from newly diagnosed lupus patients in this in vitro study. During this study, 20 recently diagnosed SLE patients and 20 healthy individuals participated. Ficoll method was used to isolate the PBMCs from whole blood, which were cultured for 48 h with Lactobacillus rhamnosus and Lactobacillus delbrueckii. In the next step, total RNA containing microRNA was extracted. cDNA was synthesized for miR-125a and miR-146a genes and analyzed by real-time PCR. Results were presented as fold changes. As compared to healthy controls, SLE patients expressed lower levels of miR-125a and miR-146a. PBMCs treated with Lactobacillus rhamnosus, Lactobacillus delbrueckii, or both probiotics had significantly higher levels of miR-125a and miR-146a compared to the untreated group. Treatment of PBMCs with both L. rhamnosus and L. delbrueckii upregulated the expression of miR-125a and miR-146a in treated cells compared with untreated cells in SLE patients (p = 0.02, p = 0.001). Lactobacillus rhamnosus and Lactobacillus delbrueckii modify lupus patients' immune responses and disease effects by regulating miR-125a and miR-146a.
Identifiants
pubmed: 38351428
doi: 10.1007/s12010-023-04827-w
pii: 10.1007/s12010-023-04827-w
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Stypińska, B., & Paradowska-Gorycka, A. (2015). Cytokines and MicroRNAs as candidate biomarkers for systemic lupus erythematosus. International Journal of Molecular Sciences, 16(10), 24194–24218.
pubmed: 26473848
pmcid: 4632746
Ahmadpoor, P., Dalili, N., & Rostami, M. (2014). An update on pathogenesis of systemic lupus erythematosus. Iranian Journal of Kidney Diseases, 8(3), 171.
pubmed: 24878938
Crispín, J. C., Liossis, S.-N. C., Kis-Toth, K., Lieberman, L. A., Kyttaris, V. C., Juang, Y.-T., & Tsokos, G. C. (2010). Pathogenesis of human systemic lupus erythematosus: Recent advances. Trends in Molecular Medicine, 16(2), 47–57.
pubmed: 20138006
pmcid: 2823952
Wu, H., Zhao, M., Chang, C., & Lu, Q. (2015). The real culprit in systemic lupus erythematosus: Abnormal epigenetic regulation. International Journal of Molecular Sciences, 16(5), 11013–11033.
pubmed: 25988383
pmcid: 4463688
Wang, H., Peng, W., Ouyang, X., Li, W., & Dai, Y. (2012). Circulating microRNAs as candidate biomarkers in patients with systemic lupus erythematosus. Translational Research, 160(3), 198–206.
pubmed: 22683424
Bartel, D. P. (2004). MicroRNAs: Genomics, biogenesis, mechanism, and function. Cell, 116(2), 281–297.
pubmed: 14744438
Dai, Y., Sui, W., Lan, H., Yan, Q., Huang, H., & Huang, Y. (2009). Comprehensive analysis of microRNA expression patterns in renal biopsies of lupus nephritis patients. Rheumatology International, 29(7), 749–754.
pubmed: 18998140
Baltimore, D., Boldin, M. P., O'Connell, R. M., Rao, D. S., & Taganov, K. D. (2008). MicroRNAs: New regulators of immune cell development and function. Nature Immunology, 9, 839.
pubmed: 18645592
Lodish, H. F., Zhou, B., Liu, G., & Chen, C.-Z. (2008). Micromanagement of the immune system by microRNAs. Nature Reviews Immunology, 8, 120.
pubmed: 18204468
Xiao, C., & Rajewsky, K. (2009). MicroRNA control in the immune system: Basic principles. Cell, 136(1), 26–36.
pubmed: 19135886
Zhou, X., Jeker, L. T., Fife, B. T., Zhu, S., Anderson, M. S., McManus, M. T., & Bluestone, J. A. (2008). Selective miRNA disruption in T reg cells leads to uncontrolled autoimmunity. Journal of Experimental Medicine, 205(9), 1983–1991.
pubmed: 18725525
pmcid: 2526194
Wang, G., Tam, L., Li, E., Kwan, B., Chow, K., Luk, C., Li, P., & Szeto, C. (2011). Serum and urinary free microRNA level in patients with systemic lupus erythematosus. Lupus, 20(5), 493–500.
pubmed: 21372198
Aronica, E., Fluiter, K., Iyer, A., Zurolo, E., Vreijling, J., Van Vliet, E., Baayen, J., & Gorter, J. (2010). Expression pattern of miR-146a, an inflammation-associated microRNA, in experimental and human temporal lobe epilepsy. European Journal of Neuroscience, 31(6), 1100–1107.
pubmed: 20214679
O'connell, R. M., Kahn, D., Gibson, W. S., Round, J. L., Scholz, R. L., Chaudhuri, A. A., Kahn, M. E., Rao, D. S., & Baltimore, D. (2010). MicroRNA-155 promotes autoimmune inflammation by enhancing inflammatory T cell development. Immunity, 33(4), 607–619.
pubmed: 20888269
pmcid: 2966521
Carlsen, A. L., Schetter, A. J., Nielsen, C. T., Lood, C., Knudsen, S., Voss, A., Harris, C. C., Hellmark, T., Segelmark, M., & Jacobsen, S. (2013). Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis and Rheumatism, 65(5), 1324–1334.
pubmed: 23401079
pmcid: 6662589
Weber, J. A., Baxter, D. H., Zhang, S., Huang, D. Y., Huang, K. H., Lee, M. J., Galas, D. J., & Wang, K. (2010). The microRNA spectrum in 12 body fluids. Clinical Chemistry, 56(11), 1733–1741.
pubmed: 20847327
pmcid: 4846276
Zhao, X., Tang, Y., Qu, B., Cui, H., Wang, S., Wang, L., Luo, X., Huang, X., Li, J., & Chen, S. (2010). MicroRNA-125a contributes to elevated inflammatory chemokine RANTES levels via targeting KLF13 in systemic lupus erythematosus. Arthritis and Rheumatism, 62(11), 3425–3435.
pubmed: 20589685
Lee, H.-M., Kim, T. S., & Jo, E.-K. (2016). MiR-146 and miR-125 in the regulation of innate immunity and inflammation. BMB Reports, 49(6), 311.
pubmed: 26996343
pmcid: 5070718
Matsuzaki, T., Takagi, A., Ikemura, H., Matsuguchi, T., & Yokokura, T. (2007). Intestinal microflora: Probiotics and autoimmunity. The Journal of Nutrition, 137(3), 798S–802S.
pubmed: 17311978
Pan, W., Zhu, S., Dai, D., Liu, Z., Li, D., Li, B., Gagliani, N., Zheng, Y., Tang, Y., & Weirauch, M. T. (2015a). MiR-125a targets effector programs to stabilize Treg-mediated immune homeostasis. Nature Communications, 6, 7096.
pubmed: 25963922
Borchers, A. T., Selmi, C., Meyers, F. J., Keen, C. L., & Gershwin, M. E. (2009a). Probiotics and immunity. Journal of Gastroenterology, 44(1), 26–46.
pubmed: 19159071
Fasano, A., & Shea-Donohue, T. (2005). Mechanisms of disease: the role of intestinal barrier function in the pathogenesis of gastrointestinal autoimmune diseases. Nature Clinical Practice. Gastroenterology & Hepatology, 2(9), 416–422.
Thomas, C. M., & Versalovic, J. (2010). Probiotics-host communication: Modulation of signaling pathways in the intestine. Gut Microbes, 1(3), 148–163.
pubmed: 20672012
pmcid: 2909492
Esmaeili, S. A., Mahmoudi, M., Momtazi, A. A., Sahebkar, A., Doulabi, H., & Rastin, M. (2017b). Tolerogenic probiotics: potential immunoregulators in systemic lupus erythematosus. Journal of Cellular Physiology, 232(8), 1994–2007.
pubmed: 27996081
Lavasani, S., Dzhambazov, B., Nouri, M., Fåk, F., Buske, S., Molin, G., Thorlacius, H., Alenfall, J., Jeppsson, B., & Weström, B. (2010). A novel probiotic mixture exerts a therapeutic effect on experimental autoimmune encephalomyelitis mediated by IL-10 producing regulatory T cells. Plos One, 5(2), e9009.
pubmed: 20126401
pmcid: 2814855
Jangi, S., Gandhi, R., Cox, L. M., Li, N., Von Glehn, F., Yan, R., Patel, B., Mazzola, M. A., Liu, S., & Glanz, B. L. (2016a). Alterations of the human gut microbiome in multiple sclerosis. Nature Communications, 7, 12015.
pubmed: 27352007
pmcid: 4931233
Schorpion, A., & Kolasinski, S. L. (2017a). Can probiotic supplements improve outcomes in rheumatoid arthritis? Current Rheumatology Reports, 19(11).
Meller, S., Winterberg, F., Gilliet, M., Müller, A., Lauceviciute, I., Rieker, J., Neumann, N. J., Kubitza, R., Gombert, M., & Bünemann, E. (2005). Ultraviolet radiation–induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis and Rheumatism, 52(5), 1504–1516.
pubmed: 15880822
Chen, J., Chia, N., Kalari, K. R., Yao, J. Z., Novotna, M., Soldan, M. M. P., Luckey, D. H., Marietta, E. V., Jeraldo, P. R., & Chen, X. (2016). Multiple sclerosis patients have a distinct gut microbiota compared to healthy controls. Scientific Reports, 6, 28484.
pubmed: 27346372
pmcid: 4921909
Zhang, X., Zhang, D., Jia, H., Feng, Q., Wang, D., Liang, D., Wu, X., Li, J., Tang, L., & Li, Y. (2015). The oral and gut microbiomes are perturbed in rheumatoid arthritis and partly normalized after treatment. Nature Medicine, 21(8), 895.
pubmed: 26214836
Zhang, H., Liao, X., Sparks, J. B., & Luo, X. M. (2014). Dynamics of gut microbiota in autoimmune lupus. Applied and Environmental Microbiology, 80(24), 7551–7560.
pubmed: 25261516
pmcid: 4249226
Mu, Q., Zhang, H., Liao, X., Lin, K., Liu, H., Edwards, M. R., Ahmed, S. A., Yuan, R., Li, L., & Cecere, T. E. (2017a). Control of lupus nephritis by changes of gut microbiota. Microbiome, 5(1), 73.
pubmed: 28697806
pmcid: 5505136
Tzang, B.-S., Liu, C.-H., Hsu, K.-C., Chen, Y.-H., Huang, C.-Y., & Hsu, T.-C. (2017). Effects of oral Lactobacillus administration on antioxidant activities and CD4+ CD25+ forkhead box P3 (FoxP3)+ T cells in NZB/W F1 mice. British Journal of Nutrition, 118(5), 333–342.
pubmed: 28901888
Zunt, J. R., Montano, S. M., Beck, I., Alarcon, J. O., Frenkel, L. M., Bautista, C. T., Price, R., & Longstreth, W. T. (2006). Human T-lymphotropic virus type 1-associated myelopathy/tropical spastic paraparesis: Viral load and muscle tone are correlated. Journal of Neurovirology, 12(6), 466–471.
pubmed: 17162662
pmcid: 2695973
Rocha, C. S., Gomes-Santos, A. C., Moreira, T. G., De Azevedo, M., Luerce, T. D., Mariadassou, M., Delamare, A. P. L., Langella, P., Maguin, E., & Azevedo, V. (2014). Local and systemic immune mechanisms underlying the anti-colitis effects of the dairy bacterium Lactobacillus delbrueckii. Plos One, 9(1), e85923.
Santos Rocha, C., Lakhdari, O., Blottière, H. M., Blugeon, S., Sokol, H., Bermu'Dez-Humara'N, L. G., Azevedo, V., Miyoshi, A., Doré, J., & Langella, P. (2011). Anti-inflammatory properties of dairy lactobacilli. Inflammatory Bowel Diseases, 18(4), 657–666.
pubmed: 21837773
Fong, F. L. Y., Kirjavainen, P., Wong, V. H. Y., & El-Nezami, H. (2015). Immunomodulatory effects of Lactobacillus rhamnosus GG on dendritic cells, macrophages and monocytes from healthy donors. Journal of Functional Foods, 13, 71–79.
Esmaeili, S. A., Mahmoudi, M., Rezaieyazdi, Z., Sahebari, M., Tabasi, N., Sahebkar, A., & Rastin, M. (2018). Generation of tolerogenic dendritic cells using Lactobacillus rhamnosus and Lactobacillus delbrueckii as tolerogenic probiotics. Journal of Cellular Biochemistry.
Isolauri, E., Kirjavainen, P., & Salminen, S. (2002). Probiotics: a role in the treatment of intestinal infection and inflammation? Gut, 50(suppl 3), iii54–iii59.
pubmed: 11953334
pmcid: 1867676
Cederholm, A., Svenungsson, E., Jensen-Urstad, K., Trollmo, C., Ulfgren, A.-K., Swedenborg, J., Fei, G.-Z., & Frostegård, J. (2005). Decreased binding of annexin V to endothelial cells: A potential mechanism in atherothrombosis of patients with systemic lupus erythematosus. Arteriosclerosis, Thrombosis, and Vascular Biology, 25(1), 198–203.
pubmed: 15539620
Tabasi, N., Rastin, M., Mahmoudi, M., Ghoryani, M., Mirfeizi, Z., Rabe, S. Z. T., & Reihani, H. (2015). Influence of vitamin D on cell cycle, apoptosis, and some apoptosis related molecules in systemic lupus erythematosus. Iranian Journal of Basic Medical Sciences, 18(11), 1107.
pubmed: 26949498
pmcid: 4764112
Vahidi, Z., Samadi, M., Mahmoudi, M., RezaieYazdi, Z., Sahebari, M., Tabasi, N., Esmaeili, S.-A., Sahebkar, A., & Rastin, M. (2018). Lactobacillus rhamnosus and Lactobacillus delbrueckii ameliorate the expression of miR-155 and miR-181a in SLE patients. Journal of Functional Foods, 48, 228–233.
O'connell, R. M., Rao, D. S., Chaudhuri, A. A., & Baltimore, D. (2010). Physiological and pathological roles for microRNAs in the immune system. Nature Reviews Immunology, 10(2), 111.
pubmed: 20098459
Pauley, K. M., & Chan, E. K. (2008). MicroRNAs and their emerging roles in immunology. Annals of the New York Academy of Sciences, 1143(1), 226–239.
pubmed: 19076353
Amarilyo, G., & La Cava, A. (2012). miRNA in systemic lupus erythematosus. Clinical Immunology, 144(1), 26–31.
pubmed: 22659032
Dai, Y., Huang, Y.-S., Tang, M., Lv, T.-Y., Hu, C.-X., Tan, Y.-H., Xu, Z.-M., & Yin, Y.-B. (2007). Microarray analysis of microRNA expression in peripheral blood cells of systemic lupus erythematosus patients. Lupus, 16(12), 939–946.
pubmed: 18042587
Tang, Y., Luo, X., Cui, H., Ni, X., Yuan, M., Guo, Y., Huang, X., Zhou, H., de Vries, N., & Tak, P. P. (2009). MicroRNA-146a contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis and Rheumatism, 60(4), 1065–1075.
pubmed: 19333922
Kim, J. K., Yuk, J.-M., Kim, S. Y., Kim, T. S., Jin, H. S., Yang, C.-S., & Jo, E.-K. (2015). MicroRNA-125a inhibits autophagy activation and antimicrobial responses during mycobacterial infection. The Journal of Immunology, 1402557.
Nowak, B., Ciszek-Lenda, M., Śróttek, M., Gamian, A., Kontny, E., Górska-Frączek, S., & Marcinkiewicz, J. (2012a). Lactobacillus rhamnosus exopolysaccharide ameliorates arthritis induced by the systemic injection of collagen and lipopolysaccharide in DBA/1 mice. Archivum Immunologiae et Therapiae Experimentalis, 60(3), 211–220.
pubmed: 22484803
Rusca, N., & Monticelli, S. (2011). MiR-146a in immunity and disease. Mol Biol Int, 2011.
Lu, L.-F., Boldin, M. P., Chaudhry, A., Lin, L.-L., Taganov, K. D., Hanada, T., Yoshimura, A., Baltimore, D., & Rudensky, A. Y. (2010). Function of miR-146a in controlling Treg cell-mediated regulation of Th1 responses. Cell, 142(6), 914–929.
pubmed: 20850013
pmcid: 3049116
Taganov, K. D., Boldin, M. P., Chang, K.-J., & Baltimore, D. (2006). NF-κB-dependent induction of microRNA miR-146, an inhibitor targeted to signaling proteins of innate immune responses. Proceedings of the National Academy of Sciences, 103(33), 12481–12486.
Esmaeili, S. A., Mahmoudi, M., Momtazi-borojeni, A. A., Sahebkar, A., Doulabi, H., & Rastin, M. (2016). Tolerogenic probiotics: Potential immunoregulators in systemic lupus erythematosus. Journal of Cellular Physiology.
Lomax, A., & Calder, P. (2009). Probiotics, immune function, infection and inflammation: A review of the evidence from studies conducted in humans. Current Pharmaceutical Design, 15(13), 1428–1518.
pubmed: 19442167
Hardy, H., Harris, J., Lyon, E., Beal, J., & Foey, A. D. (2013). Probiotics, prebiotics and immunomodulation of gut mucosal defences: Homeostasis and immunopathology. Nutrients, 5(6), 1869–1912.
pubmed: 23760057
pmcid: 3725482
Mardani, F., Mahmoudi, M., Esmaeili, S. A., Khorasani, S., Tabasi, N., & Rastin, M. (2018). In vivo study: Th1–Th17 reduction in pristane-induced systemic lupus erythematosus mice after treatment with tolerogenic Lactobacillus probiotics. Journal of Cellular Physiology.
Soccol, C. R., de Souza Vandenberghe, L. P., Spier, M. R., Medeiros, A. P., Yamaguishi, C. T., De Dea Lindner, J., Pandey, A., & Thomaz-Soccol, V. (2010). The potential of probiotics: A review. Food Technology and Biotechnology, 48(4), 413–434.
Baken, K. A., Ezendam, J., Gremmer, E. R., De Klerk, A., Pennings, J. L., Matthee, B., Peijnenburg, A. A., & Van Loveren, H. (2006). Evaluation of immunomodulation by Lactobacillus casei Shirota: Immune function, autoimmunity and gene expression. International Journal of Food Microbiology, 112(1), 8–18.
pubmed: 16875751